Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients

Blood (2018) 132 (Supplement 1): 47.

https://doi.org/10.1182/blood-2018-99-109976

Published: 2018

Journal Articles

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Susanne Saussele, MD, Johan Richter, MD PhD, Joelle Guilhot, PhD, Henrik Hjorth-Hansen, MD, Antonio Medina de Almeida, MD PhD, Jeroen J. W. M. Janssen, MD, Jiri Mayer, Prof, MD SCs, Perttu Koskenvesa, MD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Strömberg, MD PhD, Juan Luis Steegmann, MD PhD, Hanne Vestergaard, MD, Hans Ehrencrona, MD PhD, Veli Kairisto, Kateřina Machová Poláková, PhD, Martin Müller, MD, Satu Mustjoki, MDPhD, Marc G. Berger, MD PhD, Philippe Rousselot, Martine Escoffre-Barbe, MD, Gabriel Etienne, MD PhD, Jolanta Dengler, MD, Françoise Rigal-Huguet, MD, Nikolas von Bubnoff, MD, Hana Klamova, MD, Edgar Faber, MD, François Guilhot, MD, Kourosh Lotfi, MD, Delphine Rea, MD, Tim H. Brümmendorf, MD, Gorgine de Greef, MD, Leif Stenke, MD, Franck Emmanuel Nicolini, MD PhD, Laurence Legros, MD PhD, Andreas Burchert, MD, Jaroslava Voglová, MD, Aude Charbonnier, MD, Emmanuel Gyan, MDPhD, Maria-Elisabeth Goebeler, MD, Peter E. Westerweel, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 313.

https://doi.org/10.1182/blood.V130.Suppl_1.313.313

Published: 2017

Journal Articles

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Blood (2017) 130 (Supplement 1): 1624.

https://doi.org/10.1182/blood.V130.Suppl_1.1624.1624

Published: 2017

Journal Articles

Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain

Luis Felipe Casado Montero, Valentin Garcia Gutierrez, MD, Pilar Giraldo, MD PhD, Manuel Perez-Encinas, Raquel de Paz, Joaquin Martinez-Lopez, Guiomar Bautista, Santiago Osorio, Maria Jose Requena, Luis Palomera, MD PhD, Maria Jesús Peñarrubia, Carmen Calle, Jose Angel Hernandez-Rivas, Nuria García-Ormeña, Juan Luis Steegmann, MD PhD

Blood (2016) 128 (22): 3074.

https://doi.org/10.1182/blood.V128.22.3074.3074

Published: 2016

Journal Articles

ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase

Delphine Rea, MD PhD, Gianantonio Rosti, MD, Nicholas CP Cross, MA, PhD, Andrzej Hellmann, MD PhD, Dietger Niederwieser, MD, Ester Pungolino, MD, Franca Falzetti, MD, Patrizia Pregno, MD, Ester Maria Orlandi, MD, Antonio Almeida, MD PhD, Arpad Illes, MD PhD, Miguel Sagues, MD, Jens Haenig, PhD, Sharon Supekar, MSc, Seema Shah, MSc, Giuseppe Saglio, MD, Juan Luis Steegmann, MD, Michele Baccarani, MD

Blood (2016) 128 (22): 3094.

https://doi.org/10.1182/blood.V128.22.3094.3094

Published: 2016

Journal Articles

The Molecular Response at 3 Months, Measured Using a Genxpert Platform, Predicts Further Outcomes in Chronic Myeloid Patients, but the Cutoff Differs from the 10% Cutoff Commonly Used with the EUTOS Method

Valentín García Gutiérrez, María Teresa Gómez-Casares, Jose Manuel Puerta, Juan Manuel Alonso, Santiago Osorio, Juan Carlos Hernández-Boluda, Rosa Collado, Maria Jose Ramirez, MD, Fatima Ibañez, MD, Maria Luisa Martin, Juan Diego Rodriguez, Carolina Martinez-Laperche, Montse Gomez, Viviana Fiallo, Redondo Sara, Alicia Rodriguez, Concepcion Ruiz, Juan Luis Steegmann, MD, Antonio Jiménez-Velasco, MD

Blood (2016) 128 (22): 1906.

https://doi.org/10.1182/blood.V128.22.1906.1906

Published: 2016

Journal Articles

Safety and Efficacy of Dasatinib Treatment Change for Patients Previosly Treated with Imatinib with Late Warning Response. Results from the Phase II, Open, Multicenter Dasapost Study

Valentín García-Gutierrez, MD, Felipe Casado, Fermín Sánchez-Guijo, MD PhD, Rosa M. Ayala, MD PhD, Concepcion Boque, PhD, Blanca Xicoy, MD, Isabel Montero, MD, Cesar Soto, Raquel De Paz, PhD, Joaquin Martinez-Lopez, Juan Luis Steegmann, MD

Blood (2016) 128 (22): 5450.

https://doi.org/10.1182/blood.V128.22.5450.5450

Published: 2016

Journal Articles

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Blood (2016) 128 (22): 625.

https://doi.org/10.1182/blood.V128.22.625.625

Published: 2016

Journal Articles

ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy

Oliver G. Ottmann, MD, Giuliana Alimena, Daniel J. DeAngelo, MD PhD, Yeow-Tee Goh, MBBS, MMed, Michael C. Heinrich, MD, Andreas Hochhaus, MD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Francois-Xavier Mahon, MD PhD Professor, Michael J. Mauro, MD, Hironobu Minami, MD D.MDSci., Marie Huong Nguyen, MD, Delphine Rea, Juan Luis Steegmann, MD, Arkendu Chatterjee, Varsha Iyer, Noelia Martinez, Gary J. Vanasse, MD, Kim Dong-Wook, MD PhD

Blood (2015) 126 (23): 138.

https://doi.org/10.1182/blood.V126.23.138.138

Published: 2015

Journal Articles

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Blood (2015) 126 (23): 479.

https://doi.org/10.1182/blood.V126.23.479.479

Published: 2015

Journal Articles

Measurement of PTCH1 Expression at Diagnosis Is an Appropriate Tool for Tyrosine Kinase Inhibitors Selection in Chronic Myeloid Leukemia Patients in Chronic Phase

Juan Manuel Alonso-Dominguez, MD, Felipe Casado, MariaTeresa Gómez Casares, MDPhD, Ismael Buno, Francisca Ferrer-Marin, Eduardo Anguita, MD PhD, Alicia Arenas, Rafael Del Orbe, MD, Rosa M. Ayala, MD PhD, Pilar Llamas, MD, Pedro Sanchez-Godoy, MD, Carmen Burgaleta, MD, Valentín García-Gutierrez, Juan Luis Steegmann, MD PhD, Joaquin Martinez-Lopez

Blood (2015) 126 (23): 2791.

https://doi.org/10.1182/blood.V126.23.2791.2791

Published: 2015

Journal Articles

Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase

Delphine Rea, MD PhD, Gianantonio Rosti, MD, Nicholas C.P. Cross, PhD, Andrzej Hellman, MD PhD, Dietger Niederwieser, MD, Ester Pungolino, MD, Franca Falzetti, MD, Patrizia Pregno, MD, Ester Maria Orlandi, MD, Antonio Medina Almeida, Arpad Illes, MD PhD, Cristalina Fernandez, Luca Dezzani, Angela Pellegrino, Chiara Costantini, Claudia Walasek, Giuseppe Saglio, Juan Luis Steegmann, MD, Michele Baccarani

Blood (2015) 126 (23): 4040.

https://doi.org/10.1182/blood.V126.23.4040.4040

Published: 2015

Journal Articles

Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Blood (2015) 126 (23): 4054.

https://doi.org/10.1182/blood.V126.23.4054.4054

Published: 2015

Journal Articles

Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression

Valentín García-Gutierrez, Beatriz Colom-Fernandez, Anna Kreutzman, PhD, Luis Felipe Casado, Fermín Sánchez-Guijo, MD, Rosa M. Ayala, MD PhD, Concepcion Boque, PhD, Blanca Xicoy, MD PhD, Isabel Montero, MD, Cesar Soto, Raquel De Paz, Joaquin Martinez Lopez, MDPhD, Cecilia Muñoz-Calleja, Juan Luis Steegmann, MD

Blood (2015) 126 (23): 4015.

https://doi.org/10.1182/blood.V126.23.4015.4015

Published: 2015

Journal Articles

Molecular Response at 3 Months Measured with Genexpert BCR-ABL (IS) Platform Predicts Further Outcome in Chronic Myeloid Patients but the Cutoff Differs from the 10% Commonly Used with BCR-ABL (IS) EUTOS Method

Valentín García-Gutierrez, Maria Teresa Gómez Casares, Jimenez Velasco Antonio, Alonso Juan Manuel, Santiago Osorio, Juan Carlos Hernández-Boluda, Jose Manuel Puerta, Rosa Collado, Maria Jose Ramirez, Fatima IbaÃ±ez, María Luisa Martín Mateos, Juan Diego Rodriguez Gambarte, Carolina Martinez Laperche, Sara Redondo, Montse Gomez, DV Suarez Fiallo, Alicia Rodriguez Fernandez, Concepcion Ruiz, Juan Luis Steegmann, MD

Blood (2015) 126 (23): 2776.

https://doi.org/10.1182/blood.V126.23.2776.2776

Published: 2015

Journal Articles

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

Valentín García-Gutiérrez, Dragana Milojkovic, María Luisa Martín Mateos, Simone Claudiani, Concepcion Boque, PhD, Luis Felipe Casado, Gloria González, Antonio Jiménez, Alejandra Martinez Trillos, Isabel Mata Vázquez, Ángel Ramírez Payer, Alberto Álvarez Larran, Elena Amutio Díez, Abelardo Bárez García, MD, Guiomar Bautista Carrascosa, Sabela Bobillo Varela, Beatriz Cuevas Ruiz, Mª Ángeles Fernández Fernández, María del Carmen García Garay, Pilar Giraldo, MD PhD, Jose María Guinea de Castro, Natalia De Las Heras Rodríguez, MD, Nuria Hernanz Soler, Ana Iglesias Pérez, José Luis López Lorenzo, Josep Maria Martí Tutusaus, MD PhD, Rolando Omar Vallansot, Fernando Ortega Rivas, Jose Manuel Puerta, Maria Jose Ramírez Sánchez, Esperanza Romero Picos, Mario Andrés Romo Collada, Ana Rosell Mas, Silvana Saavedra Gerosa, Ana Sebrango Sadia, José Tallón Pérez, Sandra Valencia, Juan Luis Steegmann, MD

Blood (2015) 126 (23): 2786.

https://doi.org/10.1182/blood.V126.23.2786.2786

Published: 2015

Journal Articles

The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia

Markus Pfirrmann, Joerg Hasford, MD, Susanne Saussele, Anna Turkina, Prof., MD, Witold Prejzner, MD, Juan Luis Steegmann, MD, Bengt Simonsson, MD, Andrey Zaritskey, MD, Adriana Colita, MD, Daniela Zackova, MD, Jeroen Janssen, MD, Francisco Cervantes, Karel Indrak, MD, Joelle Guilhot, PhD, Ruediger Hehlmann, MD, Michele Baccarani, MD

Blood (2015) 126 (23): 595.

https://doi.org/10.1182/blood.V126.23.595.595

Published: 2015

Journal Articles

Incidence of CML in Europe—a Comparison of 19 European Countries with US SEER Data

Blood (2014) 124 (21): 3145.

https://doi.org/10.1182/blood.V124.21.3145.3145

Published: 2014

Journal Articles

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

Blood (2014) 124 (21): 3160.

https://doi.org/10.1182/blood.V124.21.3160.3160

Published: 2014

Journal Articles

Bosutinib Apears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program

Blood (2014) 124 (21): 5523.

https://doi.org/10.1182/blood.V124.21.5523.5523

Published: 2014

NARROW

Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain

ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase

The Molecular Response at 3 Months, Measured Using a Genxpert Platform, Predicts Further Outcomes in Chronic Myeloid Patients, but the Cutoff Differs from the 10% Cutoff Commonly Used with the EUTOS Method

Safety and Efficacy of Dasatinib Treatment Change for Patients Previosly Treated with Imatinib with Late Warning Response. Results from the Phase II, Open, Multicenter Dasapost Study

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Measurement of PTCH1 Expression at Diagnosis Is an Appropriate Tool for Tyrosine Kinase Inhibitors Selection in Chronic Myeloid Leukemia Patients in Chronic Phase

Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase

Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression

Molecular Response at 3 Months Measured with Genexpert BCR-ABL (IS) Platform Predicts Further Outcome in Chronic Myeloid Patients but the Cutoff Differs from the 10% Commonly Used with BCR-ABL (IS) EUTOS Method

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia

Incidence of CML in Europe—a Comparison of 19 European Countries with US SEER Data

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

Bosutinib Apears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only